Cover Image
市場調查報告書

亞太地區老年癡呆症治療藥市場:∼2021年

Alzheimer's Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

出版商 GBI Research 商品編碼 355739
出版日期 內容資訊 英文 151 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區老年癡呆症治療藥市場:∼2021年 Alzheimer's Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies
出版日期: 2016年03月01日 內容資訊: 英文 151 Pages
簡介

老年癡呆症,是特徵為認知功能障礙、記憶障礙、功能降低的進行性的神經退化性疾病,一般在60多歲的患者發病。治療藥的研究開發雖然失敗和不確定性高,但開發出許多藥物。亞太地區老年癡呆症治療藥市場,預計到2021年以年複合成長率7.9%擴大,從2014年的30億美元擴大到51億美元。

本報告提供亞太地區老年癡呆症治療藥市場相關調查,老年癡呆症的概要與治療方法,開發平台趨勢,臨床實驗趨勢,市場擴大的促進要素與阻礙等彙整資料。

第1章 目錄

第2章 簡介

  • 疾病的簡介
  • 流行病學
  • 症狀
  • 病因與病理學
  • 診斷
  • 分期
  • 預後
  • 治療方法
    • 治療流程
    • 藥物治療
    • 非藥物治療

第3章 已上市產品

  • 概要
  • 乙酰膽鹼酯酶抑製劑
  • NMDA受體拮抗劑
  • AChEI及NMDA受體拮抗劑
  • 熱圖

第4章 開發平台分析

  • 各開發階段、分子類型、給藥途徑、計劃類型開發平台
  • 各作用機制平台分析
  • 有前途的開發平台候補
  • 熱圖

第5章 臨床實驗分析

  • 失敗率
  • 臨床實驗的規模
  • 臨床實驗期間
  • 臨床實驗方法的摘要

第6章 多方案預測

  • 各地區市場
  • 亞太地區市場
  • 印度
  • 中國
  • 澳洲
  • 日本

第7章 促進要素與阻礙

  • 促進要素
    • 罹患率的上升
    • 高齡人口的醫療改革
    • 老年人的醫療保險的補償擴大
    • 民眾及政治家的認知度
    • 對前驅症狀及發病前症狀的關注
  • 障礙
    • 高(貴)的臨床實驗失敗率
    • 專利的失效和仿製藥的進入
    • 診斷老年癡呆症的神經退化進行的患者的藥物檢驗
    • 低的診斷,治療率
    • 傳統的醫療的競爭

第8章 交易與策略性聯盟

  • 授權
  • 競爭開發

第9章 附錄

圖表

目錄
Product Code: GBIHC404MR

Executive Summary

Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerable, at 559. The majority of the pipeline products are novel, and there are only seven repositioned drugs and five generic drugs. This shows progression in terms of the different molecules being developed as therapeutic agents within the AD pipeline.

Scope

The AD market has a lack of therapeutic options.

Which classes of drug dominate the market?

What newly approved therapies have entered the market?

How do the leading marketed therapies compare clinically?

How will the new therapies be positioned in the treatment of AD?

How have selected late-stage pipeline therapies performed in clinical trials?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.

Which molecular targets appear most frequently in the pipeline?

AD clinical trials have an overall attrition rate of 94%.

What are the failure rates for individual Phases of clinical development?

How do AD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?

The AD market is forecast to rise from a value of $3 billion in 2014 to $5.1 billion in 2021, at a CAGR of 7.9% across the four Asia-Pacific markets assessed.

How much of a role will disease prevalence and new product approvals play in market growth?

Will generic competition have a significant impact on the market over the forecast period?

There have been 170 licensing deals and 104 co-development deals pertaining to AD products since 2006.

Which territories show the most deal activity?

What were the trends in deal completion by product stage of development?

What were the conditions of the key licensing or co-development deals to take place in AD?

Reasons to buy

This report will allow you to:

  • Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in AD.
  • Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.
  • Analyze the AD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
  • Predict growth in market size in four Asia-Pacific markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify commercial opportunities in the AD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology and Pathophysiology
  • 2.5. Diagnosis
  • 2.6. Disease Stages
  • 2.7. Prognosis
  • 2.8. Treatment Options
    • 2.8.1. Treatment Algorithm
    • 2.8.2. Pharmacological Treatments
    • 2.8.3. Non-pharmacological Treatments

3. Marketed Products

  • 3.1. Overview
  • 3.2. Acetylcholinesterase Inhibitors
    • 3.2.1. Aricept (donepezil)-Eisai
    • 3.2.2. Exelon (rivastigmine)-Novartis
    • 3.2.3. Razadyne (galantamine)-Janssen
    • 3.2.4. Cognex (tacrine)-Shionogi
  • 3.3. NMDA Receptor Antagonists
    • 3.3.1. Namenda/Ebixa/Axura/Abixa (Memantine), Merz/Lundbeck/Forest/Daiichi Sankyo
  • 3.4. AChEI and NMDA Receptor Antagonists
    • 3.4.1. Namzaric (memantine ER + donepezil), Actavis and Adamas
  • 3.5. Heat Map-Marketed Products Overview

4. Pipeline Analysis

  • 4.1. Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
  • 4.2. Pipeline Analysis by Mechanism of Action
  • 4.3. Promising Pipeline Candidates
    • 4.3.1. MK-8931- Merck
    • 4.3.2. LMTX (methylthioninium chloride)-TauRX Therapeutics
    • 4.3.3. Gantenerumab (RG-1540)-Roche
    • 4.3.4. AZD3293-AstraZeneca
    • 4.3.5. AB1010(masitinib)-AB Science
    • 4.3.6. BIIB037-Biogen
    • 4.3.7. TTP488-vTv Therapeutics
    • 4.3.8. EVP-6124-FORUM Pharmaceuticals
    • 4.3.9. Lu AE58054-Lundbeck
    • 4.3.10. Sodium Oligomannurarate
  • 4.4. Heat Map for Pipeline Products

5. Clinical Trial Analysis

  • 5.1. Failure Rate
    • 5.1.1. Overall Failure Rate
    • 5.1.2. Failure Rate by Phase and Molecular Target
  • 5.2. Clinical Trial Size
    • 5.2.1. Patient Enrollment per Product by Stage of Development by Molecule Type and Molecular Target
    • 5.2.2. Patient Enrollment per Trial by Stage of Development by Molecule Type and Molecular Target
  • 5.3. Clinical Trial Duration
    • 5.3.1. Trial Duration by Stage of Development and Molecule Type
    • 5.3.2. Trial Duration by Stage of Development and Molecular Target
  • 5.4. Summary of Clinical Trial Metrics

6. Multi-Scenario Forecast

  • 6.1. Geographical Markets
  • 6.2. Asia-Pacific Market
  • 6.3. India
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. China
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size
  • 6.5. Australia
    • 6.5.1. Treatment Usage Patterns
    • 6.5.2. Annual Cost of Therapy
    • 6.5.3. Market Size
  • 6.6. Japan
    • 6.6.1. Treatment Usage Patterns
    • 6.6.2. Annual Cost of Therapy
    • 6.6.3. Market Size

7. Drivers and Barriers

  • 7.1. Drivers
    • 7.1.1. Rising Prevalence
    • 7.1.2. Increasing Healthcare Reforms for Elderly Population
    • 7.1.3. Increasing Health Insurance Coverage for Aged Population
    • 7.1.4. Increasing Public and Policy-Maker Awareness
    • 7.1.5. Greater Focus on Prodromal and Presymptomatic AD
  • 7.2. Barriers
    • 7.2.1. High Rate of Clinical Trial Failure
    • 7.2.2. Impending Patent Cliffs and Generic Erosion
    • 7.2.3. Drug Testing in Patients with Established AD and Advanced Neurodegeneration
    • 7.2.4. Low Diagnosis and Treatment Rate
    • 7.2.5. Additional Competition from Traditional Medicines

8. Deals and Strategic Consolidations

  • 8.1. Licensing Deals
    • 8.1.1. Deals by Region and Value
    • 8.1.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.1.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.1.4. Key Licensing Deals
  • 8.2. Co-development Deals
    • 8.2.1. Deals by Region and Value
    • 8.2.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.2.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.2.4. Key Co-development Deals

9. Appendix

  • 9.1. All Pipeline Drugs by Stage of Development
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. Phase I
    • 9.1.4. Phase II
    • 9.1.5. Phase III
  • 9.2. Market Forecasts to 2021
    • 9.2.1. Asia-Pacific
    • 9.2.2. India
    • 9.2.3. China
    • 9.2.4. Australia
    • 9.2.5. Japan
  • 9.3. Bibliography
  • 9.4. Abbreviations
  • 9.5. Research Methodology
    • 9.5.1. Secondary Research
    • 9.5.2. Marketed Product Profiles
    • 9.5.3. Late-Stage Pipeline Candidates
    • 9.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.5.5. Product Competitiveness Framework
    • 9.5.6. Pipeline Analysis
    • 9.5.7. Forecasting Model
    • 9.5.8. Deals Data Analysis
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: AD Market, Symptoms of AD at Different Stages of Disease
  • Table 2: AD Market, Symptoms of Mid Cognitive Impairment
  • Table 3: AD Market, Mini Mental State Exam
  • Table 4: AD Market, Alzheimer's Disease Assessment Scale Cognitive Subscale
  • Table 5: AD Market, Mild Cognitive Impairment Diagnosis Guidelines
  • Table 6: AD Market, Global Deterioration Scale for AD
  • Table 7: AD Market, Management of AD Symptoms
  • Table 8: AD Market, Global, Pipeline Products, Discovery, 2016
  • Table 9: AD Market, Global, Pipeline Products, Preclinical, 2016
  • Table 10: AD Market, Global, Pipeline Products, Phase I, 2016
  • Table 11: AD Market, Global, Pipeline Products, Phase II, 2016
  • Table 12: AD Market, Global, Pipeline Products, Phase III, 2016
  • Table 13: MCI Market, Asia-Pacific, Market Forecast, 2014-2021
  • Table 14: AD Market, Asia-Pacific, Market Forecast, 2014-2021
  • Table 15: AD and MCI Combined Market, Asia-Pacific, Market Forecast, 2014-2021
  • Table 16: MCI Market, India, Market Forecast, 2014-2021
  • Table 17: AD Market, India, Market Forecast, 2014-2021
  • Table 18: AD and MCI Combined Market, India, Market Forecast, 2014-2021
  • Table 19: MCI Market, China, Market Forecast, 2014-2021
  • Table 20: AD Market, China, Market Forecast, 2014-2021
  • Table 21: AD and MCI Combined Market, China, Market Forecast, 2014-2021
  • Table 22: MCI Market, Australia, Market Forecast, 2014-2021
  • Table 23: AD Market, Australia, Market Forecast, 2014-2021
  • Table 24: AD and MCI Combined Market, Australia, Market Forecast, 2014-2021
  • Table 25: MCI Market, Japan, Market Forecast, 2014-2021
  • Table 26: AD Market, Japan, Market Forecast, 2014-2021
  • Table 27: MCI and AD Combined Market, Japan, Market Forecast, 2014-2021

List of Figures

  • Figure 1: AD Market, Treatment Algorithm of AD
  • Figure 2: AD Market, Heat Map for Marketed Products
  • Figure 3: AD Market, Overall Pipeline
  • Figure 4: AD Market, Pipeline by Mechanism of Action (%)
  • Figure 5: AD Market, Asia-Pacific, Verubecestat Market Forecast ($m), 2020-2021
  • Figure 6: AD Market, Asia-Pacific, LMTX Market Forecast ($m), 2018-2021
  • Figure 7: AD Market, Asia-Pacific, Gantenerumab Market Forecast ($m), 2020-2021
  • Figure 8: AD Market, Heat Map for Pipeline Products
  • Figure 9: AD Market, Clinical Trial Failure Rates by Phase (%)
  • Figure 10: AD Market, Clinical Trial Failure Rates by Molecular Target (%)
  • Figure 11: AD Market, Clinical Trial Size per Product by Molecule Type (participants)
  • Figure 12: AD Market, Clinical Trial Size per Product by Molecular Target (participants)
  • Figure 13: AD Market, Clinical Trial Size per Trial by Molecule Type (participants)
  • Figure 14: AD Market, Clinical Trial Size per Trial by Molecular Target (participants)
  • Figure 15: AD Market, Clinical Trial Duration by Molecule Type (months)
  • Figure 16: AD Market, Clinical Trial Duration by Molecular Target (months)
  • Figure 17: AD Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 18: AD Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 19: AD and MCI Market, Asia-Pacific, Treatment Patterns (million), 2014-2021
  • Figure 20: AD and MCI Combined Market, Asia-Pacific, Treatment Patterns (million), 2014-2021
  • Figure 21: AD and MCI Market, Asia-Pacific, Market Size ($bn), 2014-2021
  • Figure 22: AD and MCI Combined Market, Asia-Pacific, Market Size ($bn), 2014-2021
  • Figure 23: AD and MCI Market, India, Treatment Patterns (million), 2014-2021
  • Figure 24: AD and MCI Combined Market, India, Treatment Patterns (million), 2014-2021
  • Figure 25: AD and MCI Market, India, Annual Cost of Therapy ($), 2014-2021
  • Figure 26: AD and MCI Market, India, Market Size ($m), 2014-2021
  • Figure 27: AD and MCI Combined Market, India, Market Size ($m), 2014-2021
  • Figure 28: AD and MCI Market, China, Treatment Patterns (million), 2014-2021
  • Figure 29: AD and MCI Combined Market, China, Treatment Patterns (million), 2014-2021
  • Figure 30: AD and MCI Market, China, Annual Cost of Therapy ($), 2014-2021
  • Figure 31: AD and MCI Market, China, Market Size ($m), 2014-2021
  • Figure 32: AD and MCI Combined Market, China, Market Size ($m), 2014-2021
  • Figure 33: AD and MCI Market, Australia, Treatment Patterns ('000), 2014-2021
  • Figure 34: AD and MCI Combined Market, Australia, Treatment Patterns ('000), 2014-2021
  • Figure 35: AD and MCI Market, Australia, Annual Cost of Therapy ($), 2014-2021
  • Figure 36: AD and MCI Market, Australia, Market Size ($m), 2014-2021
  • Figure 37: AD and MCI Combined Market, Australia, Market Size ($m), 2014-2021
  • Figure 38: AD and MCI Market, Japan, Treatment Patterns (million), 2014-2021
  • Figure 39: AD and MCI Combined Market, Japan, Treatment Patterns (million), 2014-2021
  • Figure 40: AD and MCI Market, Japan, Annual Cost of Therapy ($), 2014-2021
  • Figure 41: AD and MCI Market, Japan, Market Size ($m), 2014-2021
  • Figure 42: AD and MCI Combined Market, Japan, Market Size ($bn), 2014-2021
  • Figure 43: AD Market, Licensing Deals by Value, 2006-2015
  • Figure 44: AD Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2015
  • Figure 45: AD Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2015
  • Figure 46: AD Market, Global, Licensing Deals by Molecule Type and Value, 2006-2015
  • Figure 47: AD Market, Global, Licensing Deals by Molecular Target and Aggregate Value, 2006-2015
  • Figure 48: AD Market, Global, Co-development Deals by Value, 2006-2015
  • Figure 49: AD Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2015
  • Figure 50: AD Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2015
  • Figure 51: AD Market, Global, Co-development Deals by Molecule Type and Value, 2006-2015
  • Figure 52: AD Market, Global, Licensing Deals by Molecular Target and Aggregate Value, 2006-2015
Back to Top